Spectrum Pharmaceuticals, Inc. (SPPI) Sinks On Qapzola Finding

An FDA advisory committee ruled against Spectrum Pharmaceuticals, Inc.'s (NASDAQ:SPPI) cancer drug

Sep 14, 2016 at 2:27 PM
facebook X logo linkedin

Unlike this fellow biotech, shares of Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) are sinking, after the company said a Food and Drug Administration (FDA) advisory committee concluded SPPI's cancer drug, Qapzola, did not show substantial improvement over a placebo. While the FDA can still vote to approve the drug in its final ruling in mid-December, SPPI stock is down 5.3% this afternoon at $5.20, after earlier being halted for volatility.

This negative price action is nothing new for SPPI, though. Since hitting its most recent high at $7.16 in early August, the shares have shed more than one-quarter of their value -- due in large part to an earnings-induced bear gap on Aug. 10. In fact, today's plunge has Spectrum Pharmaceuticals on track for its lowest daily close since early March.

On the sentiment front, some short sellers could be kicking themselves for missing out on this latest drop, considering short interest declined nearly 13% in the two most recent reporting periods. However, there's still a lofty 7.4 million SPPI shares sold short, or 7.8 times the stock's average daily pace of trading.

Elsewhere, the shares of Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) could be at risk of getting hit with a round of negative analyst notes. Of the three brokerages covering SPPI, two maintain a "strong buy" rating, with not a single "sell" to be found. Plus, the average 12-month price target of $9.25 stands at a stiff 88% premium to current trading levels. Bearish brokerage notes could create more headwinds for the shares.

Sign up now for Schaeffer's Market Recap to get all the day's big stock movers, must-know technical levels, and top economic stories straight to your inbox.

Target Effortless Triple-Digit Gains Every Sunday Evening For Life!

This is your chance to triple your profit potential on Sunday evenings, without spending all your free time watching the market.

On Sundays, as a Weekend Plus subscriber, you’ll get up to 6 trades every Sunday, each targeting gains of 200% or more.

Start targeting gains like the ones our subscribers have seen recently, including:

213.3% GAIN on AutoNation calls
100.0% GAIN on Monster Beverage calls
100.4% GAIN on Walgreens Boots Alliance puts
100.4% GAIN on ON Semiconductor calls
257.7% GAIN on Dell calls

101.0% GAIN on Apollo Global Management calls
103.6% GAIN on JP Morgan  Chase calls
105.3% GAIN on DraftKings calls
101.3% GAIN on Airbnb calls
203.0% GAIN on Shopify calls
102.0% GAIN on Cboe Global Markets calls
100.9% GAIN on Boeing calls
102.1% GAIN on Microsoft puts
102.3% GAIN on First Solar calls
101.5% GAIN on PulteGroup calls
101.0% GAIN on Apple calls
209.4% GAIN on NXP Semiconductors calls
100.8% GAIN on Uber Technologies calls
100.4% GAIN on Academy Sports and Outdoors puts
102.2% GAIN on Trade Desk calls
100.8% GAIN on DoorDash calls
100.0% GAIN on Camping World Holdings puts
100.0% GAIN on Cboe Global Markets calls
100.2% GAIN on C3.ai calls
238.5% GAIN on Oracle calls



Rainmaker Ads CGI